The value of remote care in the reduction of healthcare utilization in implantable cardioverter-defibrillator patients

被引:1
|
作者
van Steenbergen, Gijs [1 ]
Ben Jaddi, Oumaima [2 ]
Theuns, Dominic [2 ]
van Veghel, Dennis [1 ]
Dekker, Lukas [1 ,3 ]
Simmers, Tim [1 ]
机构
[1] Catharina Hosp, Catharina Heart Ctr, Eindhoven, Netherlands
[2] Erasmus MC, Thoraxctr, Dept Cardiol, Rotterdam, Netherlands
[3] Eindhoven Univ Technol, Dept Biomed Technol, Eindhoven, Netherlands
来源
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY | 2021年 / 44卷 / 12期
关键词
cardiac resynchronization-therapy; healthcare utilization; implantable cardioverter defibrillator; remote care; telemonitoring; HEART-FAILURE PATIENTS; FOLLOW-UP; ELECTRONIC DEVICES; EXPERT CONSENSUS; MANAGEMENT; EFFICACY;
D O I
10.1111/pace.14390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Minimal evidence is available of the reduction in healthcare utilization of remote care in ICD patients over a longer period of follow-up. Objectives This study compared healthcare utilization up to 3 year follow-up in implantable cardioverter-defibrillator (ICD) patients with remote care compared to conventional care. Methods We conducted a retrospective cohort study of patients who received a single or dual-chamber ICD or cardiac resynchronization therapy-defibrillator (CRT-D) between 2016 and 2018. Patients with remote care and patients were compared with patients with received conventional care (control group). The primary endpoint was a composite of cardiac follow-up visits, ICD follow-up visits, telephone consultations, emergency department (ED) visits and hospital admissions and was defined as total healthcare utilization. The secondary endpoints were the individual care activities and one-year all-cause mortality. Results A total of 497 patients were included in the study, of which 299 patients were allocated to the remote care and 198 patients to the control group. Mean follow-up was 815 +/- 279 days. Remote care was associated with a significantly lower rate of adjusted total healthcare utilization in comparison to the control group that sustained for 3 subsequent follow-up years (IRR = 0.78, 95% CI [0.67 to 0.92], p < .01). One-year all-cause mortality was similar between the remote care and control group (respectively 3.0% vs. 5.5%, p = .29). Conclusions Compared to the standard follow-up of in-office care, a remote care program was associated with a sustained lower rate of planned and unplanned healthcare utilization up to 3 subsequent years after ICD/CRT-D implantation.
引用
收藏
页码:2005 / 2014
页数:10
相关论文
共 50 条
  • [1] Patients with Pacemaker or Implantable Cardioverter-Defibrillator
    Schulman, Peter M.
    Rozner, Marc A.
    Sera, Valerie
    Stecker, Eric C.
    MEDICAL CLINICS OF NORTH AMERICA, 2013, 97 (06) : 1051 - +
  • [2] Impact of remote monitoring on the management of arrhythmias in patients with implantable cardioverter-defibrillator
    Marcantoni, Lina
    Toselli, Tiziano
    Urso, Giulia
    Pratola, Claudio
    Ceconi, Claudio
    Bertini, Matteo
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2015, 16 (11) : 775 - 781
  • [3] Time until diagnosis of clinical events with different remote monitoring systems in implantable cardioverter-defibrillator patients
    Soth-Hansen, Malene
    Witt, Christoffer Tobias
    Rasmussen, Mathis
    Kristensen, Jens
    Gerdes, Christian
    Nielsen, Jens Cosedis
    HEART RHYTHM, 2018, 15 (11) : 1648 - 1654
  • [4] Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions
    Gojkovic, Olivera
    Aliot, Etienne M.
    Capucci, Alessandro
    Connolly, Stuart J.
    Crijns, Harry
    Hohnloser, Stefan H.
    Kulakowski, Piotr
    Roy, Denis
    Radzik, David
    Singh, Bramah N.
    Kowey, Peter R.
    HEART RHYTHM, 2012, 9 (02) : 217 - U2
  • [5] Development of the Implantable Cardioverter-Defibrillator
    Maron, Barry J.
    Estes, N. A. Mark
    Rowin, Ethan J.
    Maron, Martin S.
    Reynolds, Matthew R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (04) : 353 - 373
  • [6] Utilization Effects of the Affordable Care Act on Implantable Cardioverter-Defibrillator Therapy
    Madias, Christopher
    Parzynski, Craig S.
    Burrows, Austin
    Minges, Karl E.
    Curtis, Jeptha P.
    Doukky, Rami
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (14) : 1714 - 1717
  • [7] The implantable cardioverter-defibrillator
    Greene, HL
    CLINICAL CARDIOLOGY, 2000, 23 (05) : 315 - 326
  • [8] No News is Good News: Remote Monitoring of Implantable Cardioverter-Defibrillator Patients
    Skov, Mikael B.
    Johansen, Pauline G.
    Skov, Charlotte S.
    Lauberg, Astrid
    CHI 2015: PROCEEDINGS OF THE 33RD ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, 2015, : 827 - 836
  • [9] Safety of Outpatient Implantation of the Implantable Cardioverter-defibrillator
    Datino, Tomas
    Miracle Blanco, Angel
    Nunez Garcia, Alberto
    Gonzalez-Torrecilla, Esteban
    Atienza Fernandez, Felipe
    Arenal Maiz, Angel
    Hernandez-Hernandez, Jesus
    Avila Alonso, Pablo
    Eidelman, Gabriel
    Fernandez-Aviles, Francisco
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (07): : 579 - 584
  • [10] Prophylactic implantable cardioverter-defibrillator in the very elderly
    Zakine, Cyril
    Garcia, Rodrigue
    Narayanan, Kumar
    Gandjbakhch, Estelle
    Algalarrondo, Vincent
    Lellouche, Nicolas
    Perier, Marie-Cecile
    Fauchier, Laurent
    Gras, Daniel
    Bordachar, Pierre
    Piot, Olivier
    Babuty, Dominique
    Sadoul, Nicolas
    Defaye, Pascal
    Deharo, Jean-Claude
    Klug, Didier
    Leclercq, Christophe
    Extramiana, Fabrice
    Boveda, Serge
    Marijon, Eloi
    EUROPACE, 2019, 21 (07): : 1063 - 1069